Figure 7.
Western blot data in (A) and (B) reveal that VEGF expression was 42.9% lower in the bumetanide-treated tumors than in the control tumors after 3 weeks of therapy (p=0.021). The IHC images in (C) support this result and show that, much like CD31, a decrease in VEGF expression (red) is associated with greater levels of hypoxia (green).